Buy 2+ vials to unlock bundle savings (5% / 10% / 15%). Add more to reach $150 for free shipping.
Overview
Retatrutide is an investigational peptide designed to activate the GLP-1, GIP, and glucagon receptors simultaneously. As a triple receptor agonist, it represents an important area of ongoing research in metabolic science.
Mechanism
Retatrutide is studied as a triple agonist at GLP-1, GIP, and glucagon receptors. Multi-receptor activation is investigated for effects on energy expenditure, glucose metabolism, and appetite-related signaling in metabolic research.
Areas of Active Scientific Research
Current research is exploring its effects on metabolic regulation, energy expenditure, appetite signaling, glucose metabolism, and body composition. Its multi-receptor approach has generated considerable scientific interest for advancing the understanding of complex metabolic pathways.
Molecular Characteristics
- Molecular weight
- ~4858 Da
- Formula
- Synthetic peptide (triple agonist)
- Sequence
- Investigational triple incretin/glucagon receptor agonist peptide
- Appearance
- Lyophilized powder, white to pale solid, research-grade presentation.
- Dose
- 10mg
- Grade
- Research grade (RUO)
Storage Recommendations
For laboratory research use only. Store lyophilized material at −20°C or below. Reconstitute and handle according to institutional SOPs for peptide research.
Purity
Target purity ≥99% by HPLC for this research-grade batch. See the Certificate of Analysis for batch-specific analytical results.
≥99.0%
Batch Number
Current batch identifier for traceability and COA lookup:
PL-RET-10-26042
Date Tested: 2026-04-18
Certificate of Analysis
Retatrutide 10mg · Third-party verified batch documentation
- Laboratory Name
- Independent Analytical Laboratory (ISO/IEC 17025)
- Purity %
- ≥99.0%
- Batch Number
- PL-RET-10-26042
- Date Tested
- 2026-04-18
What a COA demonstrates
Batch-specific identity verification, purity by validated analytical methods (e.g. HPLC), and third-party laboratory testing records for the referenced lot.
What a COA does not demonstrate
Clinical efficacy, safety for human or veterinary use, or suitability for any application outside qualified laboratory research.
Quality Assurance
Every Prime Labs peptide undergoes rigorous quality control procedures and is accompanied by batch specific analytical documentation to support identity and purity verification.
References
Selected peer-reviewed literature for research context. Prime Labs citations do not constitute therapeutic claims.
- Jastreboff A.M. et al. — Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. New England Journal of Medicine, 2023.